Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Radiation treatment for patients with intermediate-risk prostate cancer.

Greene DE, Mayadev JS, Valicenti RK.

Ther Adv Urol. 2012 Jun;4(3):113-24. doi: 10.1177/1756287212442977.

3.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
4.

Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.

Park S, Meng MV, Elkin EP, Speight JL, DuChane J, Carroll PR.

J Urol. 2005 Nov;174(5):1802-7.

PMID:
16217291
5.

Controversies in prostate cancer radiotherapy: consensus development.

Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L; Canadian GU Radiation Oncologist Group.

Can J Urol. 2001 Aug;8(4):1314-22. Review.

PMID:
11564274
6.

Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.

Koontz BF, Chino J, Lee WR, Hahn CA, Buckley N, Huang S, Kim J, Reagan R, Joyner R, Anscher MS.

Brachytherapy. 2009 Apr-Jun;8(2):191-6. doi: 10.1016/j.brachy.2009.01.002.

PMID:
19433320
7.

A systematic overview of radiation therapy effects in prostate cancer.

Nilsson S, Norlén BJ, Widmark A.

Acta Oncol. 2004;43(4):316-81. Review.

PMID:
15303499
8.

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S.

BJU Int. 2012 Feb;109 Suppl 1:22-9. doi: 10.1111/j.1464-410X.2011.10827.x. Review.

9.

Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation.

Stock RG, Yalamanchi S, Hall SJ, Stone NN.

J Urol. 2010 Feb;183(2):546-50. doi: 10.1016/j.juro.2009.10.006. Epub 2009 Dec 14. Erratum in: J Urol. 2010 Apr;183(4):1650. Yamalachi, Swati [corrected to Yalamanchi, Swati].

PMID:
20006854
10.

Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.

Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V.

Radiother Oncol. 2012 Aug;104(2):181-6. doi: 10.1016/j.radonc.2012.07.003. Epub 2012 Jul 30.

PMID:
22853851
12.

Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.

Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. doi: 10.1016/j.ijrobp.2008.10.071. Epub 2009 Mar 14.

PMID:
19289266
13.

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.

BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30.

14.

Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.

Rosenberg JE, Chen MH, Nguyen PL, Braccioforte MH, Moran BJ, D'Amico AV.

Clin Genitourin Cancer. 2012 Mar;10(1):21-5. doi: 10.1016/j.clgc.2011.10.003. Epub 2011 Nov 29.

PMID:
22130293
15.

High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer.

Zwahlen DR, Andrianopoulos N, Matheson B, Duchesne GM, Millar JL.

Brachytherapy. 2010 Jan-Mar;9(1):27-35. doi: 10.1016/j.brachy.2009.04.007. Epub 2009 Oct 20.

PMID:
19846348
16.
17.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
18.
19.

High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.

Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J.

Prostate Cancer Prostatic Dis. 2006;9(3):245-53. Epub 2006 Jun 20.

PMID:
16786040

Supplemental Content

Support Center